Literature DB >> 10805105

Tumor necrosis factor-alpha expression in muscles of polymyositis and dermatomyositis.

S Kuru1, A Inukai, Y Liang, M Doyu, A Takano, G Sobue.   

Abstract

We evaluated the expression of tumor necrosis factor-alpha (TNF-alpha) mRNA in muscle biopsy specimens from patients with polymyositis (PM) and dermatomyositis (DM) to clarify its role in the pathogenesis of PM and DM. We performed non-radioactive in situ hybridization studies for TNF-alpha combined with immunohistochemistry for cell type-specific markers on muscles from ten PM and five DM patients. TNF-alpha-positive infiltrating cells present in the endomysium and perimysium were found in all PM and DM muscles. The frequency of TNF-alpha-positive cells against total infiltrating cells was similar among PM and DM (27.1 +/- 7.4% in PM and 28.5 +/- 13.6% in DM). However, TNF-alpha/CD8-positive lymphocytes and TNF-alpha-positive macrophages invading the non-necrotic muscle fiber were observed only in PM but not in DM. TNF-alpha was more highly expressed in PM and DM than was previously thought, and it was suggested that TNF-alpha plays a role in muscle fiber degeneration in PM.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10805105     DOI: 10.1007/s004010051165

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  20 in total

1.  A randomized, double-blind, placebo-controlled trial of infliximab in refractory polymyositis and dermatomyositis.

Authors:  Adam Schiffenbauer; Megha Garg; Christine Castro; Angelina Pokrovnichka; Galen Joe; Joseph Shrader; Imelda Victoria Cabalar; Sara Faghihi-Kashani; Michael O Harris-Love; Paul H Plotz; Frederick W Miller; Mark Gourley
Journal:  Semin Arthritis Rheum       Date:  2017-10-16       Impact factor: 5.532

2.  Contribution of tumour necrosis factor alpha and interleukin (IL) 1beta to IL6 production, NF-kappaB nuclear translocation, and class I MHC expression in muscle cells: in vitro regulation with specific cytokine inhibitors.

Authors:  G Chevrel; C Granet; P Miossec
Journal:  Ann Rheum Dis       Date:  2005-02-24       Impact factor: 19.103

3.  A randomized, pilot trial of etanercept in dermatomyositis.

Authors: 
Journal:  Ann Neurol       Date:  2011-06-17       Impact factor: 10.422

4.  TNF-alpha induces macroautophagy and regulates MHC class II expression in human skeletal muscle cells.

Authors:  Christian W Keller; Claudia Fokken; Stuart G Turville; Anna Lünemann; Jens Schmidt; Christian Münz; Jan D Lünemann
Journal:  J Biol Chem       Date:  2010-10-27       Impact factor: 5.157

Review 5.  Biologic therapy in the idiopathic inflammatory myopathies.

Authors:  Thomas Khoo; Vidya Limaye
Journal:  Rheumatol Int       Date:  2019-11-04       Impact factor: 2.631

6.  Successful treatment for conventional treatment-resistant dermatomyositis-associated interstitial lung disease with adalimumab.

Authors:  Jin-Kyoung Park; Han-Gyul Yoo; Dae-Seon Ahn; Hyun-Soon Jeon; Wan-Hee Yoo
Journal:  Rheumatol Int       Date:  2011-11-17       Impact factor: 2.631

7.  Aberrant cell cycle reentry in human and experimental inclusion body myositis and polymyositis.

Authors:  Bumsup Kwon; Pravir Kumar; Han-Kyu Lee; Ling Zeng; Kenneth Walsh; Qinghao Fu; Amey Barakat; Henry W Querfurth
Journal:  Hum Mol Genet       Date:  2014-02-20       Impact factor: 6.150

Review 8.  The role of Jo-1 in the immunopathogenesis of polymyositis: current hypotheses.

Authors:  Dana P Ascherman
Journal:  Curr Rheumatol Rep       Date:  2003-12       Impact factor: 4.592

Review 9.  Cutaneous dermatomyositis in the era of biologicals.

Authors:  Natalie A Wright; Ruth Ann Vleugels; Jeffrey P Callen
Journal:  Semin Immunopathol       Date:  2015-11-12       Impact factor: 9.623

10.  Possible role for tumour necrosis factor inhibitors in the treatment of resistant dermatomyositis and polymyositis: a retrospective study of eight patients.

Authors:  P Efthimiou; S Schwartzman; L J Kagen
Journal:  Ann Rheum Dis       Date:  2006-02-13       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.